ArticleJournal of thoracic disease2026
Effect of dezocine on the median effective dose of sufentanil for blunting hemodynamic responses to endotracheal intubation during anesthesia induction.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In clinical practice, dezocine has been used to inhibit sufentanil-induced cough (SIC). The aim of the study was to evaluate the effect of dezocine on the required dose of sufentanil for blunting hemodynamic responses during anesthesia induction and endotracheal intubation in male and female patients. Methods: Adult patients of both sexes with American Society of Anesthesiologists physical status I-II (ASA I-II) undergoing general anesthesia and endotracheal intubation were enrolled. Peri-intubation hemodynamic variables including blood pressure and heart rate were recorded. The Dixon up‑and‑down method was used to calculate the median effective dose (ED50) of sufentanil for attenuating intubation-related hemodynamic reactions. A dose-response curve was generated by the probit analysis in each group. Results: In females, the ED50 of sufentanil for suppressing intubation responses was 0.23±0.03 µg/kg in the control group and 0.26±0.05 µg/kg in the dezocine group, with no significant between-group difference (P>0.05). In males, the corresponding ED50 values were 0.35±0.03 and 0.43±0.04 µg/kg, respectively (P<0.05). Probit analysis showed that in females, the ED50 [95% confidence interval (CI)] was 0.219 (0.183-0.248) µg/kg in the control group and 0.241 (0.192-0.282) µg/kg in the dezocine group. In males, the ED50 (95% CI) was 0.339 (0.291-0.374) µg/kg and 0.409 (0.357-0.472) µg/kg, respectively. Probit analysis showed that in females, the ED50 (95% CI) was 0.219 (0.183-0.248) µg/kg in the control group and 0.241 (0.192-0.282) µg/kg in the dezocine group. In males, the ED50 (95% CI) was 0.339 (0.291-0.374) µg/kg and 0.409 (0.357-0.472) µg/kg, respectively. Conclusions: Dezocine increases the sufentanil dose requirement for blunting intubation-related hemodynamic responses in male patients, while no obvious influence is observed in female patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.